History Preserved: A Guide to New York City Landmarks and Historic Districts Harmon H. Goldstone Martha Dalrymple

Autor: RATH,, FREDERICK L.

Publikováno v: New York History, 1975 Apr 01. 56(2), 250-251.

Externí odkaz: https://www.jstor.org/stable/43460445

Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial

Autor: David I Marks, Amy A Kirkwood, Clare J Rowntree, Melanie Aguiar, Katharine E Bailey, Brendan Beaton, Paul Cahalin, Anna Z Castleton, Laura Clifton-Hadley, Mhairi Copland, Anthony H Goldstone, Richard Kelly, Emma Lawrie, SooWah Lee, Andrew K McMillan, Mary Frances McMullin, Tobias F Menne, Rachel J Mitchell, Anthony V Moorman, Bela Patel, Pip Patrick, Paul Smith, David Taussig, Deborah Yallop, Krisztina Zuborne Alapi, Adele K Fielding

Publikováno v: Marks, D I, Kirkwood, A A, Rowntree, C J, Aguiar, M, Bailey, K E, Beaton, B, Cahalin, P, Castleton, A Z, Clifton-Hadley, L, Copland, M, Goldstone, A H, Kelly, R, Lawrie, E, Lee, S, McMillan, A K, McMullin, M F, Menne, T F, Mitchell, R J, Moorman, A V, Patel, B, Patrick, P, Smith, P, Taussig, D, Yallop, D, Alapi, K Z & Fielding, A K 2022, ' Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial ', The Lancet Haematology, vol. 9, no. 4, pp. e262-e275 . https://doi.org/10.1016/S2352-3026(22)00038-2

BACKGROUND: Treatment for adults with acute lymphoblastic leukaemia requires improvement. UKALL14 was a UK National Cancer Research Institute Adult ALL group study that aimed to determine the benefit of adding the anti-CD20 monoclonal antibody, ritux

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eeb76af476ccd2c9482ebad9b933c975
https://doi.org/10.1016/s2352-3026(22)00038-2

Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial

Autor: Ruth Pettengell, Ariane Boumendil, Joanna Romejko-Jarosinska, R Johnson, Peter Dreger, Stephen P. Robinson, Alejandro Martín, Eva Kimby, N. Schmitz, P Giri, Carsten Utoft Niemann, Anthony H. Goldstone, Isabelle Bence-Bruckler, Bernd Metzner, Silvia Montoto, Ruzena Uddin

Publikováno v: Bone Marrow Transplantation. 56:1413-1421

We report the 12-year follow-up of the prospective randomized EBMT LYM1 trial to determine whether the benefit of brief duration rituximab maintenance (RM) on progression-free survival (PFS) in patients with relapsed follicular lymphoma (FL) receivin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1c505b8f93f04f2831c98fa7b98d651
https://doi.org/10.1038/s41409-020-01182-w

At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial

Autor: Martin S. Tallman, Susan M. Richards, Xin V. Wang, David I. Marks, Anthony H. Goldstone, Charles G. Mullighan, Jacob M. Rowe, Mark R. Litzow, Georgina Buck, Peter H. Wiernik, Kathryn G. Roberts, Letizia Foroni, Cheryl L. Willman, Dan Douer, Chezi Ganzel, Hillard M. Lazarus, Elisabeth Paietta, Selina M. Luger

Publikováno v: British Journal of Haematology

Summary Late relapse [>3 years from complete remission (CR)] in acute lymphoblastic leukaemia (ALL), is unusual. Data from the MRC UKALLXII/ECOG E2993 trial are presented to evaluate the incidence and characteristics of late relapse in adult ALL. Of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88d6ea8189d0e49891bebd2e18da8009
https://doi.org/10.1111/bjh.16616

The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial

Autor: David I. Marks, Anthony V. Moorman, Lucy Chilton, Elisabeth Paietta, Amir Enshaie, Gordon DeWald, Christine J. Harrison, Adele K. Fielding, Letizia Foroni, Anthony H. Goldstone, Mark R. Litzow, Selina M. Luger, Andrew K. McMillan, Janis Racevskis, Jacob M. Rowe, Martin S. Tallman, Peter Wiernik, Hillard M. Lazarus

Publikováno v: Haematologica, Vol 98, Iss 6 (2013)

The biology and outcome of adult t(4;11)(q21;q23)/MLL-AFF1 acute lymphoblastic leukemia are poorly understood. We describe the outcome and delineate prognostic factors and optimal post-remission therapy in 85 consecutive patients (median age 38 years

Externí odkaz: https://doaj.org/article/e001fb0cab064bd3a4369c1e67f8e80a